Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


1 Anticancer Res
3 BMC Cancer
1 Br J Radiol
1 Clin Cancer Res
1 Eur Radiol
4 Eur Urol
1 J Clin Oncol
1 J Magn Reson Imaging
2 J Nucl Med
1 J Urol
1 Magn Reson Med
1 Nat Rev Urol
1 PLoS One
2 Prostate
2 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Anticancer Res

  1. TAMBURO M, Buffettino E, Pepe P, Marletta G, et al
    Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
    Anticancer Res. 2024;44:2205-2210.
    PubMed         Abstract available

    BMC Cancer

  2. IHEANACHO CO, Enechukwu OH
    Role of antihypertensive medicines in prostate cancer: a systematic review.
    BMC Cancer. 2024;24:542.
    PubMed         Abstract available

  3. OBINATA D, Takayama K, Lawrence MG, Funakoshi D, et al
    Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    BMC Cancer. 2024;24:554.
    PubMed         Abstract available

  4. YANG L, Ruan Y, Xu H
    HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis.
    BMC Cancer. 2024;24:544.
    PubMed         Abstract available

    Br J Radiol

  5. Correction to: High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.
    Br J Radiol. 2024 Apr 30:tqae083. doi: 10.1093.

    Clin Cancer Res

  6. APARICIO AM, Tidwell RSS, Yadav SS, Chen JS, et al
    A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740.
    PubMed         Abstract available

    Eur Radiol

    Refining clinical decision strategies and prostate cancer detection through fine adjustments in the combination of PSA-derived parameters and MRI.
    Eur Radiol. 2024 Apr 29. doi: 10.1007/s00330-024-10734.

    Eur Urol

  8. TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al
    EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
    PubMed         Abstract available

  9. OST P, Siva S, Zilli T
    OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
    Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.

  10. HU JC, Vickers AJ, Schaeffer EM
    Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate
    Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.

  11. CHAKRABARTI D, Parker CC
    Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
    Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.

    J Clin Oncol

  12. SAYAN M, Chen MH, Loffredo M, McMahon E, et al
    Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
    J Clin Oncol. 2024 May 1:JCO2302394. doi: 10.1200/JCO.23.02394.
    PubMed         Abstract available

    J Magn Reson Imaging

  13. ABRAHAMSEN BS, Tandstad T, Aksnessaether BY, Bogsrud TV, et al
    Added Value of [18F]PSMA-1007 PET/CT and PET/MRI in Patients With Biochemically Recurrent Prostate Cancer: Impact on Detection Rates and Clinical Management.
    J Magn Reson Imaging. 2024 Apr 28. doi: 10.1002/jmri.29386.
    PubMed         Abstract available

    J Nucl Med

  14. MORADI TUCHAYI A, Yadav S, Jiang F, Kim ST, et al
    Real-World Experience with (177)Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
    J Nucl Med. 2024;65:735-739.
    PubMed         Abstract available

  15. UNTERRAINER LM, Ruchalski K, Allen-Auerbach MS, Calais J, et al
    PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have?
    J Nucl Med. 2024 Jan 4:jnumed.123.266722. doi: 10.2967/jnumed.123.266722.

    J Urol

  16. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
    J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
    PubMed         Abstract available


  17. CORNU JN
    Outcomes Following Localized Prostate Cancer Treatment.
    JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5489.

  18. HUANG TB, Ding XF
    Outcomes Following Localized Prostate Cancer Treatment.
    JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5486.

  19. BAROCAS DA, Al Hussein Al Awamlh B, Koyama T
    Outcomes Following Localized Prostate Cancer Treatment-Reply.
    JAMA. 2024 Apr 29. doi: 10.1001/jama.2024.5492.

  20. HARRIS E
    Prostate Cancer Cases Might Rise to 3 Million Globally by 2040.
    JAMA. 2024 May 3. doi: 10.1001/jama.2024.6729.

    Magn Reson Med

  21. GUNDOGDU B, Medved M, Chatterjee A, Engelmann R, et al
    Self-supervised multicontrast super-resolution for diffusion-weighted prostate MRI.
    Magn Reson Med. 2024;92:319-331.
    PubMed         Abstract available

    Nat Rev Urol

  22. NI X, Wei Y, Li X, Pan J, et al
    From biology to the clinic - exploring liver metastasis in prostate cancer.
    Nat Rev Urol. 2024 Apr 26. doi: 10.1038/s41585-024-00875.
    PubMed         Abstract available

    PLoS One

  23. RAJANALA SH, Ghale R, Nandakumar S, Chadalavada K, et al
    Quantifying Y chromosome loss in primary and metastatic prostate cancer by chromosome painting.
    PLoS One. 2024;19:e0301989.
    PubMed         Abstract available


  24. MIYAHIRA AK, Kamran SC, Jamaspishvili T, Marshall CH, et al
    Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24721.
    PubMed         Abstract available

  25. KARSH L, Du S, He J, Waters D, et al
    Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24720.
    PubMed         Abstract available


  26. VAN DER EECKEN H, Vansevenant B, Devos G, Roussel E, et al
    Nutritional supplement with fermented soy in men with an elevated risk of prostate cancer and negative prostate biopsies: General and oncological results from the prospective PRAECAP trial.
    Urology. 2024 Apr 24:S0090-4295(24)00300-5. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available

  27. BOLOGNA E, Licari LC, Franco A, Ditonno F, et al
    Incidence and Management of Radiation Cystitis After Pelvic Radiotherapy for Prostate Cancer: Analysis from a National Database.
    Urology. 2024 Apr 29:S0090-4295(24)00308-X. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.